Akero Therapeutics/$AKRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Ticker

$AKRO
Sector
Health
Primary listing
NASDAQ

Employees

67
Headquarters
South San Francisco, United States
Website
akerotx.com

AKRO Metrics

BasicAdvanced
$3.5B
-
-$3.78
-0.28
-

What the Analysts think about AKRO

Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.

Bulls say / Bears say

The peer-reviewed Phase 2b SYMMETRY trial published in the New England Journal of Medicine on May 9, 2025 showed that 29% of patients receiving EFX 50 mg achieved at least a 1-stage improvement in fibrosis at Week 96 without MASH worsening versus 11% for placebo in the ITT analysis (p=0.031), representing the first significant evidence of cirrhosis reversal in MASH.
Akero’s cash, cash equivalents, and marketable securities totaled $1,086.2 million as of June 30, 2025, which provides funding through 2028 to support its Phase 3 SYNCHRONY program.
At the EASL Congress 2025, new analyses from the Phase 2b HARMONY trial showed that over 50% of pre-cirrhotic (F2-F3) patients treated with 50 mg EFX were responders by all three measures—qFibrosis® AI, ELF score, and FibroScan®—compared to less than 5% of placebo patients, underscoring strong anti-fibrotic effects.
The Phase 2b SYMMETRY study failed to meet its primary endpoint at Week 36, with EFX groups showing numerical but not statistically significant fibrosis improvement compared to placebo, raising concerns about the reliability of early surrogate endpoints.
Akero will not report its first Phase 3 efficacy results until the first half of 2026 from the SYNCHRONY Real-World study, so clinical and regulatory prospects remain dependent on upcoming trial performance.
Research and development expenses increased 25% year-over-year to $69.3 million in Q2 2025, driven by rising costs from late-stage trials and higher operating expenses, while Akero still has no approved products generating revenue.
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

AKRO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AKRO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

AKRO News

AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Accesswire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AKRO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs